$3.5M Study Tests Psilocybin for Cocaine Addiction

For the first time, researchers will rigorously test whether psilocybin combined with psychotherapy can help people break free from cocaine addiction.

Dr. Albert Arias, chief of addiction psychiatry at Carilion Clinic, just received a $623,000 award from the National Institute on Drug Abuse to launch the study. If the initial phase succeeds, total funding could reach $3.5 million for a full clinical trial.

The timing matters deeply. Cocaine use disorder devastates patients, families, and entire communities, yet doctors have no FDA-approved medication to offer. When people seek help for cocaine addiction today, treatment options remain frustratingly limited.

This research will test psilocybin, a psychedelic compound, administered in carefully controlled clinical settings alongside structured therapy sessions. The first phase will examine safety, proper dosing, and early signs the treatment might work.

Previous studies have shown promise for psychedelic-assisted therapy in treating alcohol and nicotine addiction. But research on stimulant disorders like cocaine addiction remains rare, making this trial especially important.

Dr. Arias emphasizes the team isn't assuming psilocybin works. Instead, they're asking the question carefully and scientifically. If they find evidence of benefit, it could lay groundwork for larger studies and eventually new treatment options for patients who desperately need them.

Why This Inspires

This research represents hope grounded in rigorous science. Rather than leaving people with cocaine use disorder without options, researchers are pursuing innovative approaches that could transform addiction treatment.

The study also reflects a broader shift in psychiatric medicine. Compounds once dismissed are now being seriously investigated through proper clinical trials. That willingness to explore new possibilities, while maintaining strict safety standards, could help thousands of families currently facing addiction without adequate tools.

If successful, this research won't just help individuals recover. It could reshape how we approach stimulant addiction treatment entirely, giving doctors and patients a powerful new option where none existed before.

The trial launches soon, bringing scientific rigor to a question that could change lives.